The Effect of Rituximab on Vaccine Responses in Patients with Immune Thrombocytopenia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Jul 16

PMID 23851398

Citations 89

Authors

Ishac Nazi

John G Kelton

Mark Larche

Denis P Snider

Nancy M Heddle

Mark A Crowther

Richard J Cook

Alan T Tinmouth

Joy Mangel

Donald M Arnold

Affiliations

Soon will be listed here.

Abstract

B-cell depletion may impair vaccine responses and increase infection risk in patients with immune thrombocytopenia (ITP). We investigated the effects of rituximab on antibody and cellular responses to Streptococcus pneumoniae polysaccharide and Haemophilus influenzae type b (Hib) vaccines in ITP patients. Of 60 patients in the main trial, 24 patients received both vaccines 6 months after rituximab (n = 17) or placebo (n = 7). Among 20 evaluable patients, 3 of 14 (21%) in the rituximab group and 4 of 6 (67%) in the placebo group achieved a fourfold increase in anti-pneumococcal antibodies (P = .12). For anti-Hib antibodies, 4 of 14 (29%) and 5 of 6 (83%), respectively, achieved a fourfold increase (P < .05). Fewer patients in the rituximab group demonstrated Hib killing (2 of 14 [14%], 5 of 6 [83%], P < .05). Three of 14 rituximab-treated patients failed to respond to vaccines by any criteria. After vaccinations, preplasma cell blasts and interferon-γ-secreting T cells were reduced in rituximab-treated patients. Antibody responses were impaired for at least 6 months after rituximab. Cellular immunity was reduced in parallel with depleted B-cell pools. These findings have implications for the timing of vaccinations and the mechanism of infection after rituximab in ITP patients.

Citing Articles

Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study.

Castellino A, Comba L, Bertolotti L, Boccomini C, Clerico M, Nicoli P Ann Hematol. 2025; .

PMID: 40074837 DOI: 10.1007/s00277-025-06295-0.

The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium.

McGovern D, Jones R, Jayne D, Smith R Drugs. 2025; 85(3):325-341.

PMID: 39969779 DOI: 10.1007/s40265-024-02143-z.

Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study.

Zadro Y, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G Blood Adv. 2024; 9(1):231-238.

PMID: 39189926 PMC: 11788127. DOI: 10.1182/bloodadvances.2024013067.

SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis.

Baxter R, Cabrera-Martinez B, Ghosh T, Rester C, Moreno M, Borko T Immunohorizons. 2024; 8(3):254-268.

PMID: 38483384 PMC: 10985059. DOI: 10.4049/immunohorizons.2300108.

Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors-Literature Review and Statement of Experts from Polish Dermatological Society.

Narbutt J, Zuber Z, Lesiak A, Bien N, Szepietowski J Vaccines (Basel). 2024; 12(1).

PMID: 38250895 PMC: 10820194. DOI: 10.3390/vaccines12010082.

References

Cooper N, Arnold D . The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010; 149(1):3-13. DOI: 10.1111/j.1365-2141.2010.08076.x. View

Stasi R, Del Poeta G, Stipa E, Evangelista M, Trawinska M, Cooper N . Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110(8):2924-30. DOI: 10.1182/blood-2007-02-068999. View

Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa M . Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010; 12(3):R111. PMC: 2911904. DOI: 10.1186/ar3047. View

Portielje J, Westendorp R, Kluin-Nelemans H, Brand A . Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97(9):2549-54. DOI: 10.1182/blood.v97.9.2549. View

Paris K, Sorensen R . Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. 2007; 99(5):462-4. DOI: 10.1016/S1081-1206(10)60572-8. View

Yri O, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T . Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011; 118(26):6769-71. DOI: 10.1182/blood-2011-08-372649. View

Pescovitz M, Torgerson T, Ochs H, Ocheltree E, McGee P, Krause-Steinrauf H . Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol. 2011; 128(6):1295-1302.e5. PMC: 3659395. DOI: 10.1016/j.jaci.2011.08.008. View

Hottinger A, George A, Bel M, Favet L, Combescure C, Meier S . A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist. 2012; 17(3):436-45. PMC: 3316930. DOI: 10.1634/theoncologist.2011-0342. View

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

10.

Thomsen R, Schoonen W, Farkas D, Riis A, Jacobsen J, Fryzek J . Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med. 2009; 151(8):546-55. DOI: 10.7326/0003-4819-151-8-200910200-00008. View

11.

Issa N, Marty F, Gagne L, Koo S, Verrill K, Alyea E . Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010; 17(3):434-8. PMC: 3262168. DOI: 10.1016/j.bbmt.2010.10.002. View

12.

Eisenberg R, Jawad A, Boyer J, Maurer K, McDonald K, Luning Prak E . Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2012; 33(2):388-96. PMC: 3565069. DOI: 10.1007/s10875-012-9813-x. View

13.

MacKay H, McGee J, Villa D, Gubbay J, Tinker L, Shi L . Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol. 2010; 50(3):212-6. DOI: 10.1016/j.jcv.2010.11.013. View

14.

Fernandes J, Wasserman S, Snider D . Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus-diphtheria vaccine. Vaccine. 2009; 28(6):1493-8. DOI: 10.1016/j.vaccine.2009.11.057. View

15.

Horwitz S, Negrin R, Blume K, Breslin S, Stuart M, Stockerl-Goldstein K . Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2003; 103(3):777-83. DOI: 10.1182/blood-2003-04-1257. View

16.

Romero-Steiner S, Spear W, Brown N, Holder P, Hennessy T, Gomez de Leon P . Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin Diagn Lab Immunol. 2004; 11(1):89-93. PMC: 321360. DOI: 10.1128/cdli.11.1.89-93.2004. View

17.

Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K . Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011; 63(6):1486-96. DOI: 10.1002/art.30325. View

18.

Konradsen H, Rasmussen C, Ejstrud P, Hansen J . Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect. 1997; 119(2):167-74. PMC: 2808838. DOI: 10.1017/s0950268897007978. View

19.

Carson K, Evens A, Richey E, Habermann T, Focosi D, Seymour J . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113(20):4834-40. PMC: 2686134. DOI: 10.1182/blood-2008-10-186999. View

20.

Cho C, Hwang W, Cheng S, Lee T, Teng C . Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma. Ann Hematol. 2010; 90(1):111-2. DOI: 10.1007/s00277-010-0962-9. View